Cancer of Pancreas Clinical Trial
Official title:
Phase II Clinical Study on Resectable or Borderline Resectable Pancreas Adenocarcinoma Preoperative Treatment With Chemotherapy and Carbon Ions Radiation Therapy (Hadrontherapy)
Relapses free survival will be evaluated as efficacy of carbon ions radiation therapy released before surgery.
Enrolled subjects will undergo to 3 cycles of Folfirinox before re-evaluation of the lesion. Then, 4D planning and imaging with respiratory gating end rescanning technique will be adopted to calculate the optimal treatment plan to carbon ions radiation therapy: 38.4 Gy[RBE] is the prescribed dose to CTV. 4.8 Gy[RBE]/fraction will be delivered 4 times a week in two weeks. 4/6 weeks after hadrontherapy, after a CT scan with contrast, patient will undergo to a surgery. After 4/6 weeks, Gemcitabine will be administered for 6 cycles. Secondary endpoints of the trial are overall survival, resectability rate (operable vs borderline operable), acute toxicity within 3 months, 3-6 months, over 6 months. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02902484 -
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04008537 -
Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device
|
N/A | |
Recruiting |
NCT04809935 -
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
|
Phase 4 | |
Not yet recruiting |
NCT03659292 -
Effects of Epidural Block on the Prognosis in Patients With Pancreatic Cancer Undergoing Distal Pancreatectomy
|
N/A | |
Completed |
NCT03150615 -
Enteral Nutrition After Pancreaticoduodenectomy
|
N/A | |
Recruiting |
NCT02682394 -
Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas
|
N/A | |
Recruiting |
NCT05566743 -
A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas
|
Phase 2 | |
Not yet recruiting |
NCT04049461 -
Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer
|
||
Recruiting |
NCT04164602 -
The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
|
||
Active, not recruiting |
NCT04128332 -
Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer
|
N/A | |
Recruiting |
NCT03536793 -
Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
|
||
Recruiting |
NCT02311439 -
Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas
|
Phase 2/Phase 3 | |
Completed |
NCT02296736 -
The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan
|
||
Withdrawn |
NCT04123574 -
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
|
Early Phase 1 | |
Not yet recruiting |
NCT03278015 -
Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT02905578 -
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
|
Phase 2 | |
Completed |
NCT01446458 -
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT04677244 -
Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level
|
N/A | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Recruiting |
NCT06148298 -
Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
|